Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
Eli Muchtar(Mayo Clinic), Shaji Kumar(Mayo Clinic), P. Leif Bergsagel(Mayo Clinic in Arizona), David Dingli, Dania K. Helgeson, Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Amie Fonder, Yi L. Hwa, Betsy LaPlant(Mayo Clinic), Erin E. Bradt, Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Mustaqeem Siddiqui(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Patrick O’Brien(Quantitative BioSciences), Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, Jeremy T. Larsen(City of Hope)
Cited by 10
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k